{"id":481650,"title":"Notice: Prescription Drug List (PDL): Multiple additions [2021-09-10] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T17:11:36.306000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2021-09-10.html?wbdisable=true","snippet":"Notice: Prescription Drug List (PDL): Multiple Additions Date: September 10, 2021 Our file number: 21-116232-170 The purpose of this Notice of Amendment is to notify about the additions of: Elexacaftor, Inclisiran, Ospemifene, Pralsetinib and Tafasitamab to the Prescription Drug…","rawSnapshotUrl":"/api/snapshots/raw/481650","browseUrl":"https://replay.healtharchive.ca/job-6/20260106171136/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2021-09-10.html?wbdisable=true#ha_snapshot=481650","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}